Outcome Measurepharmacokinetics

C max

Maximum Plasma Concentration

3 Papers in Blossom

Outcome Data Across Studies

Reported results for C max across 3 studies with quantitative data.

Outcome data across 5 study arm–timepoint observations
					SD
Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients 2016Secondary	Noribogaine 60mg(experimental)	0	6	81.6	23.8	—
Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients 2016Secondary	Noribogaine 120mg(experimental)	0	6	172.8	32.1	—
Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients 2016Secondary	Noribogaine 180mg(experimental)	0	6	267.9	46.9	—
Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study 2025Safety	5-MeO-DMT 12 mg(experimental)	20	9	2.2	—	—
Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study 2025Secondary	BPL-003(experimental)	1.9	10	24.0	3.7	—

Papers Using C max

Paywallindividual

Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study

This Phase I clinical trial (n=36) of sublingual 5-MeO-DMT (6-12 mg weekly doses over four weeks) in adults with moderate to high anxiety/depression demonstrated good safety and tolerability with no significant adverse events, rapid absorption with peak plasma concentrations at 20 minutes, dose-dependent neurophysiological modulation without full psychedelic effects, and maintenance of normal cognitive and behavioral function.

Published: July 15, 2025
Journal: Neuropsychopharmacology
Authors: Beatriz, M., Millón, B., Noguera, L., Bruno, D., Vita, L., Zanino, M., Kassuha, D. E., Ortiz, J. E., Feresin, G. E., Díaz-Dellavalle, P., Orosco, L., Garcés, M. A., Diez, P., Albarracín, S. G., Bruno, M. A.

Open Accessindividual

Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study

This open-label study (n=10) investigates the effects of single-dose psilocybin (25mg) therapy in adults with severe alcohol use disorder (AUD). It finds significant reductions in alcohol consumption, craving, and increases in self-efficacy over 12 weeks following treatment despite notable between-participant pharmacokinetic variations.

Published: February 28, 2025
Journal: Journal of Psychopharmacology
Authors: Fink-Jensen, A., Jensen, M. E., Stenbæk, D. S., Messell, C. D., Poulsen, E. D., Varga, T. V., Fisher, P. M., Nielsen, M. K. K., Johansen, S. S., Volkow, N. D., Knudsen, G. M.

Paywallindividual

Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients

In a randomized, double‑blind, placebo‑controlled single ascending‑dose study in 27 opioid‑dependent patients, noribogaine was generally well tolerated with dose‑linear pharmacokinetics (t1/2 24–30 h) but caused a concentration‑dependent QTcI prolongation (mean increases ≈16, 28 and 42 ms at 60, 120 and 180 mg) and mostly mild adverse events (visual changes, headache, nausea). There was a non‑significant trend to reduced opioid withdrawal scores, most apparent at 120 mg, but study design limits efficacy conclusions and supports planned exposure‑controlled multiple‑dose trials.

Published: April 1, 2016
Journal: Clinical Pharmacology in Drug Development
Authors: Glue, P., Cape, G., Tunnicliff, D., Lockhart, M., Lam, F., Hung, N., Tak Hung, C., Harland, S., Devane, J., Crockett, R. S., Howes, J., Darpo, B., Zhou, M., Weis, H., Friedhoff, L., Buckland, H.

Quick Facts

Full Name: Maximum Plasma Concentration
Domain: pharmacokinetics
Papers Indexed: 3
Unit: ng/mL

All Measures